Format

Send to

Choose Destination
See comment in PubMed Commons below
Dermatology. 2007;215(3):240-4.

Thalidomide in the treatment of Kaposi's sarcoma.

Author information

1
Department of Clinical Medicine and Immunological Sciences, Section of Dermatology, University of Siena, Siena, Italy. rubegni@unisi.it

Abstract

BACKGROUND:

Kaposi's sarcoma (KS) is a lymphangioproliferative tumour. Therapy of KS depends on the characteristics of the disease, especially area and growth rate of lesions, and patient condition. Currently symptomatic resectable lesions are excised, whereas more advanced disease and unresectable lesions are treated with radiotherapy. If a large area or internal organs are affected or other treatments fail, chemotherapy is used. Recently some authors have reported their encouraging experience in the use of thalidomide in patients with AIDS-related KS.

OBJECTIVE:

To evaluate the efficacy of thalidomide in 3 patients with non-AIDS-related KS.

METHODS:

Two patients with classic widespread cutaneous and 1 with iatrogenic cutaneous and visceral KS were treated with thalidomide (100 mg/day) for 12 months.

RESULTS:

In all 3 patients partial remission was evident after 4 months of thalidomide therapy; in 2 out of 3 complete remission was achieved after 12 months of treatment.

CONCLUSIONS:

Our results seem to confirm the utility of thalidomide in the treatment of non-AIDS-related KS.

PMID:
17823523
DOI:
10.1159/000106583
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Support Center